Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.
Also called NCT02729025
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 129 participants
- Sponsor
- Registry
-
NCT02729025 -
2015-003731-35
-
- Other papers using this trial's data
- Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT02729025. Randomized; triple masking; primary purpose treatment. Start 2016-04-14 (actual); primary completion 2018-04-05 (actual). Results posted on 2019-04-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
- Acronym
- ANITSCHKOW
- Condition
- Subjects With Hyperlipidemia, Dyslipidemia
- Intervention (Drug)
- Evolocumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct02729025- Content hash
ab7c59506cf414764ff825e98df6dae63c85fa58db97b73d137e9f40186c4116